NIKKEI 225
38,405.66 +470.90 (+1.24%) HANG SENG
17,763.03 +16.12 (+0.09%) CRUDE OIL
81.78 -0.85 (-1.03%) GOLD FUTURES
2,306.80 -50.90 (-2.16%) DOW
38,018.33 -367.76 (-0.96%) Bitcoin GBP
50,119.69 -539.11 (-1.06%)
CSL Ltd (CSJ.DU)
| Previous close | 166.86 |
| Open | 167.08 |
| Bid | 165.90 x 0 |
| Ask | 168.60 x 0 |
| Day's range | 166.14 - 167.08 |
| 52-week range | 135.10 - 192.50 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
GlobeNewswireMark Cuban Foundation and CSL Bring AI Bootcamp to Philadelphia Teens
Applications for camp that offers free world-class AI education to help prepare students for latest tech evolution are now openPHILADELPHIA, April 30, 2024 (GLOBE NEWSWIRE) -- The Mark Cuban Foundation, in partnership with CSL, is bringing the only artificial intelligence (AI) camp of its kind, free of charge, to high school students in Philadelphia. With a custom and highly-relevant curriculum focused on teaching students about the latest developments in the world of AI and Generative AI, the c
- GlobeNewswire
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat dose PK/PD study of neffy under NAC conditions and updated testing concerning nitrosamine levels Exclusive licensing deal for Australia and New Zealand with CSL Seqirus; CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialization of neffy. ARS Pharmaceutical
GlobeNewswireTravere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with p
